CU23575A1 - Composición farmacéutica que comprende la proteína nmb0606 - Google Patents

Composición farmacéutica que comprende la proteína nmb0606

Info

Publication number
CU23575A1
CU23575A1 CU20060075A CU20060075A CU23575A1 CU 23575 A1 CU23575 A1 CU 23575A1 CU 20060075 A CU20060075 A CU 20060075A CU 20060075 A CU20060075 A CU 20060075A CU 23575 A1 CU23575 A1 CU 23575A1
Authority
CU
Cuba
Prior art keywords
composition
nmb0606
pharmaceutical composition
composition including
protein
Prior art date
Application number
CU20060075A
Other languages
English (en)
Inventor
Acosta Karem Cobas
Diaz Darien Garcia
Negrin Yasser Perera
Garcia Gretel Sardinas
Feyt Rolando Pajon
Blanco Sonia Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20060075A priority Critical patent/CU23575A1/es
Priority to CNA2007800182864A priority patent/CN101448518A/zh
Priority to CA002647465A priority patent/CA2647465A1/en
Priority to AU2007234214A priority patent/AU2007234214A1/en
Priority to EP07721809A priority patent/EP2011509A2/en
Priority to BRPI0709922-3A priority patent/BRPI0709922A2/pt
Priority to PCT/CU2007/000013 priority patent/WO2007112703A2/es
Priority to MX2008012665A priority patent/MX2008012665A/es
Priority to US12/295,198 priority patent/US20100129387A1/en
Priority to ARP070101323A priority patent/AR060797A1/es
Priority to KR1020087026335A priority patent/KR20080108576A/ko
Priority to ZA200808768A priority patent/ZA200808768B/xx
Priority to NO20084525A priority patent/NO20084525L/no
Publication of CU23575A1 publication Critical patent/CU23575A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con el campo de la medicina, particularmente con el desarrollo de una composición farmacéutica que comprende la proteína NMB0606. La composición de la presente invención confiere protección contra diferentes enfermedades, causadas o no por patógenos. La proteína NMB0606 se identificó como componente de las preparaciones de vesículas de membrana externa (VME) de Neisseria meningitidis, se obtuvo mediante la tecnología del ácido desoxirribonucleico (ADN) recombinante y se evaluó su inmunogenicidad y actividad protectora en modelos animales. Por el elevado grado de conservación del gen que codifica para la proteína NMB0606, la composición que la comprende posee alto valor como antígeno inductor de una respuesta inmune de amplia reactividad. La composición de esta invención es aplicable en la medicina humana.
CU20060075A 2006-03-31 2006-03-31 Composición farmacéutica que comprende la proteína nmb0606 CU23575A1 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CU20060075A CU23575A1 (es) 2006-03-31 2006-03-31 Composición farmacéutica que comprende la proteína nmb0606
CNA2007800182864A CN101448518A (zh) 2006-03-31 2007-03-29 含有nmb0606蛋白的药物组合物
CA002647465A CA2647465A1 (en) 2006-03-31 2007-03-29 Pharmaceutical composition containing the nmb0606 protein
AU2007234214A AU2007234214A1 (en) 2006-03-31 2007-03-29 Pharmaceutical composition containing the NMB0606 protein
EP07721809A EP2011509A2 (en) 2006-03-31 2007-03-29 Pharmaceutical composition containing the nmb0606 protein
BRPI0709922-3A BRPI0709922A2 (pt) 2006-03-31 2007-03-29 composiÇço farmacÊutica contendo a proteÍna nmb0606
PCT/CU2007/000013 WO2007112703A2 (es) 2006-03-31 2007-03-29 Composición farmacéutica que comprende la proteína nmb0606
MX2008012665A MX2008012665A (es) 2006-03-31 2007-03-29 Composicion farmaceutica que comprende la proteina nmb0606.
US12/295,198 US20100129387A1 (en) 2006-03-31 2007-03-29 Pharmaceutical composition containing the nmb0606 protein
ARP070101323A AR060797A1 (es) 2006-03-31 2007-03-29 Composicion farmaceutica que comprende la proteina nmb0606
KR1020087026335A KR20080108576A (ko) 2006-03-31 2007-03-29 Ｎｍｂ0606 단백질을 포함하는 약학적 조성물
ZA200808768A ZA200808768B (en) 2006-03-31 2008-10-14 Pharmaceutical composition containing the NMB0606 protein
NO20084525A NO20084525L (no) 2006-03-31 2008-10-28 Farmasoytiske sammensetninger inneholdende NMB0606-protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060075A CU23575A1 (es) 2006-03-31 2006-03-31 Composición farmacéutica que comprende la proteína nmb0606

Publications (1)

Publication Number Publication Date
CU23575A1 true CU23575A1 (es) 2010-09-30

Family

ID=38535626

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060075A CU23575A1 (es) 2006-03-31 2006-03-31 Composición farmacéutica que comprende la proteína nmb0606

Country Status (13)

Country Link
US (1) US20100129387A1 (es)
EP (1) EP2011509A2 (es)
KR (1) KR20080108576A (es)
CN (1) CN101448518A (es)
AR (1) AR060797A1 (es)
AU (1) AU2007234214A1 (es)
BR (1) BRPI0709922A2 (es)
CA (1) CA2647465A1 (es)
CU (1) CU23575A1 (es)
MX (1) MX2008012665A (es)
NO (1) NO20084525L (es)
WO (1) WO2007112703A2 (es)
ZA (1) ZA200808768B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Vaccines US Inc. Neisseria meningitidis vaccine
EP4007600A4 (en) * 2019-08-01 2023-08-23 Trustees of Tufts College VACCINE COMPOSITIONS AND ANTIGEN SELECTION METHODS
WO2025077785A1 (zh) * 2023-10-10 2025-04-17 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010721A (pt) * 1999-05-19 2002-06-11 Chiron Spa Composições de neisserias combinadas
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
CU23236A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P

Also Published As

Publication number Publication date
BRPI0709922A2 (pt) 2011-07-26
MX2008012665A (es) 2008-10-13
AU2007234214A1 (en) 2007-10-11
CA2647465A1 (en) 2007-10-11
ZA200808768B (en) 2009-07-29
WO2007112703A3 (es) 2008-04-24
WO2007112703A2 (es) 2007-10-11
NO20084525L (no) 2008-11-28
EP2011509A2 (en) 2009-01-07
US20100129387A1 (en) 2010-05-27
KR20080108576A (ko) 2008-12-15
CN101448518A (zh) 2009-06-03
AR060797A1 (es) 2008-07-16

Similar Documents

Publication Publication Date Title
McAuley et al. Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
BRPI0924460A2 (pt) composição farmacêutica para uso em oftalmologia médica e veterinária
MX340541B (es) Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
BR112012022800A2 (pt) composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
PT2285408T (pt) Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
BRPI0906710B8 (pt) peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) , peptídeo e composição farmacêutica
ECSP12011959A (es) SALES DE 4-[2-[[5-METIL-1-(2-NAFTALENIL)-1H-PIRAZOL-3-il]OXI]ETIL]MORFOLINA
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
MX2020005235A (es) Celula humana transformada y uso de la misma.
EA201690115A1 (ru) Комбинированные иммуногенные композиции
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
NZ712713A (en) Attenuated swine influenza vaccines and methods of making and use thereof
AR060796A1 (es) Composicion farmaceutica que comprende la proteina nmb0938
AR060797A1 (es) Composicion farmaceutica que comprende la proteina nmb0606
CU23584A1 (es) Composición farmacéutica que comprende la proteína nmb1796
BR112015013625A2 (pt) adjuvante de vacinação, preparação e vacinas contendo o mesmo
BRPI0606614A2 (pt) peptìdeos para distribuição de vacinas na mucosa
CU23549A1 (es) Composiciones farmacéuticas que contienen la proteína nma0939
BR112014007491A2 (pt) sequências de aminoácidos para o controle de patógenos